Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868663 | 0.83 | TSHR (0.57) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL3881644 | 0.83 | TSHR (0.57) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL1860261 | 0.82 | POLB (0.52) | POLBALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL1860263 | 0.82 | POLB (0.52) | POLBALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL1865320 | 0.82 | HSD11B1 (0.52) | POLBALDH1A1MAPK1MAPTGAA | |
| SCHEMBL12991579 | 0.82 | ALDH1A1 (0.51) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL3629662 | 0.81 | POLB (0.53) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL972842 | 0.81 | KDM2B (0.51) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL972843 | 0.81 | KDM2B (0.51) | POLBALDH1A1MAPK1MAPTL3MBTL1 | |
| SCHEMBL1861675 | 0.81 | RAB9A (0.53) | POLBALDH1A1MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7858624-B2 | Piperidine and morpholine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | POLB 1750/4885ALDH1A1 587/4885MAPK1 1192/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | POLB 1384/4885ALDH1A1 1084/4885MAPK1 1494/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | POLB 1750/4885ALDH1A1 587/4885MAPK1 1192/4885 |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | REN, ACE, PREP | POLB 670/4885ALDH1A1 2168/4885MAPK1 1239/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | POLB 1077/4885ALDH1A1 1060/4885MAPK1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.